Spliced X-Box binding protein 1 predicts satisfying responsiveness and survival benefit toward bortezomib-based therapy in multiple myeloma patients

References

• Medical Masterclass c, Firth J. Haematology: multiple myeloma. Clin Med (Lond). 2019;19(1):58–60. doi:10.7861/clinmedicine.19-1-58
   PubMed Web of Science ®Google Scholar
• Joshua DE, Bryant C, Dix C, et al. Biology and therapy of multiple myeloma. Med J Aust. 2019;210(8):375–380. doi:10.5694/mja2.50129
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Lussier T, Schoebe N, Mai S. Risk stratification and treatment in smoldering multiple myeloma. Cells. 2022;11(1. doi:10.3390/cells11010130
   PubMed Web of Science ®Google Scholar
• Podar K, Leleu X. Relapsed/refractory multiple myeloma in 2020/2021 and beyond. Cancers (Basel). 2021;13(20. doi:10.3390/cancers13205154
   Web of Science ®Google Scholar
• Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2021;32(3):309–322. doi:10.1016/j.annonc.2020.11.014
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the international myeloma working group. Blood. 2016;127(24):2955–2962. doi:10.1182/blood-2016-01-631200
   PubMed Web of Science ®Google Scholar
• Hemminki K, Forsti A, Hansson M. Incidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in Sweden up to year 2016. Sci Rep. 2021;11(1):17272. doi:10.1038/s41598-021-96804-8
   PubMed Web of Science ®Google Scholar
• Yang FY, Wang HF, Xia LH, et al. A propensity score matching study of autologous hematopoietic stem cell transplantation and New drug chemotherapy for newly diagnosed multiple myeloma. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022;30(1):158–165.
   PubMedGoogle Scholar
• Yoshida H, Nadanaka S, Sato R, et al. XBP1 is critical to protect cells from endoplasmic reticulum stress: evidence from site-2 protease-deficient Chinese hamster ovary cells. Cell Struct Funct. 2006;31(2):117–125. doi:10.1247/csf.06016
   PubMed Web of Science ®Google Scholar
• Xu W, Wang C, Hua J. X-box binding protein 1 (XBP1) function in diseases. Cell Biol. Int. 2021;45(4):731–739. doi:10.1002/cbin.11533
   PubMed Web of Science ®Google Scholar
• Zhang D, De Veirman K, Fan R, et al. ER stress arm XBP1s plays a pivotal role in proteasome inhibition-induced bone formation. Stem Cell Res Ther. 2020;11(1):516. doi:10.1186/s13287-020-02037-3
   PubMed Web of Science ®Google Scholar
• Bujisic B, De Gassart A, Tallant R, et al. Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth. Blood. 2017;129(17):2420–2428. doi:10.1182/blood-2016-09-741348
   PubMed Web of Science ®Google Scholar
• Luo X, Alfason L, Wei M, et al. Spliced or unspliced, that Is the question: The biological roles of XBP1 isoforms in pathophysiology. Int J Mol Sci. 2022;23(5).
   Web of Science ®Google Scholar
• Park SM, Kang TI, So JS. Roles of XBP1s in transcriptional regulation of target genes. Biomedicines. 2021;9(7).
   Web of Science ®Google Scholar
• Song M, Sandoval TA, Chae CS, et al. IRE1α–XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity. Nature. 2018;562(7727):423–428. doi:10.1038/s41586-018-0597-x
   PubMed Web of Science ®Google Scholar
• Ji H, Huang C, Wu S, et al. XBP1-s promotes colorectal cancer cell proliferation by inhibiting TAp73 transcriptional activity. Biochem Biophys Res Commun. 2019;508(1):203–209. doi:10.1016/j.bbrc.2018.11.112
   PubMed Web of Science ®Google Scholar
• Wu S, Du R, Gao C, et al. The role of XBP1s in the metastasis and prognosis of hepatocellular carcinoma. Biochem Biophys Res Commun. 2018;500(3):530–537. doi:10.1016/j.bbrc.2018.04.033
   PubMed Web of Science ®Google Scholar
• Besse L, Besse A, Kraus M, et al. High immunoproteasome activity and sXBP1 in pediatric precursor B-ALL predicts sensitivity towards proteasome inhibitors. Cells. 2021;10(11). doi:10.3390/cells10112853
   PubMed Web of Science ®Google Scholar
• Cui Y, Xu H, Yang Y, et al. The regulation of miR-320a/XBP1 axis through LINC00963 for endoplasmic reticulum stress and autophagy in diffuse large B-cell lymphoma. Cancer Cell Int. 2021;21(1):305. doi:10.1186/s12935-021-01992-y
   PubMed Web of Science ®Google Scholar
• Borjan B, Kern J, Steiner N, et al. Spliced XBP1 levels determine sensitivity of multiple myeloma cells to proteasome inhibitor bortezomib independent of the unfolded protein response mediator GRP78. Front Oncol. 2020;9:1530. doi:10.3389/fonc.2019.01530
   PubMed Web of Science ®Google Scholar
• Ludwig H, Miguel JS, Dimopoulos MA, et al. International myeloma working group recommendations for global myeloma care. Leukemia. 2014;28(5):981–992. doi:10.1038/leu.2013.293
   PubMed Web of Science ®Google Scholar
• Durie BG, Salmon SE. A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842–854. doi:10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U
   PubMed Web of Science ®Google Scholar
• Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–3420. doi:10.1200/JCO.2005.04.242
   PubMed Web of Science ®Google Scholar
• Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: A report from international myeloma working group. J Clin Oncol. 2015;33(26):2863–2869. doi:10.1200/JCO.2015.61.2267
   PubMed Web of Science ®Google Scholar
• Wang Y, Osakue D, Yang E, et al. Endoplasmic reticulum stress response of trabecular meshwork stem cells and trabecular meshwork cells and protective effects of activated PERK pathway. Invest Ophthalmol Vis Sci. 2019;60(1):265–273. doi:10.1167/iovs.18-25477
   PubMed Web of Science ®Google Scholar
• Moreau P, Avet-Loiseau H, Facon T, et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood. 2011;118(22):5752–5758. quiz 5982. doi:10.1182/blood-2011-05-355081
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: Report of the international myeloma workshop consensus panel 1. Blood. 2011;117(18):4691–4695. doi:10.1182/blood-2010-10-299487
   PubMed Web of Science ®Google Scholar
• Bortolozzi R, Viola G, Porcu E, et al. A novel copper(I) complex induces ER-stress-mediated apoptosis and sensitizes B-acute lymphoblastic leukemia cells to chemotherapeutic agents. Oncotarget. 2014;5(15):5978–5991. doi:10.18632/oncotarget.2027
   PubMedGoogle Scholar
• Bae J, Hideshima T, Zhang GL, et al. Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma. Leukemia. 2018;32(3):752–764. doi:10.1038/leu.2017.316
   PubMed Web of Science ®Google Scholar
• Reimold AM, Iwakoshi NN, Manis J, et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature. 2001;412(6844):300–307. doi:10.1038/35085509
   PubMed Web of Science ®Google Scholar
• Todd DJ, McHeyzer-Williams LJ, Kowal C, et al. XBP1 governs late events in plasma cell differentiation and is not required for antigen-specific memory B cell development. J Exp Med. 2009;206(10):2151–2159. doi:10.1084/jem.20090738
   PubMed Web of Science ®Google Scholar
• Chen L, Li Q, She T, et al. IRE1α-XBP1 signaling pathway, a potential therapeutic target in multiple myeloma. Leuk Res. 2016;49:7–12. doi:10.1016/j.leukres.2016.07.006
   PubMed Web of Science ®Google Scholar
• Tavernier Q, Mami I, Rabant M, et al. Urinary angiogenin reflects the magnitude of kidney injury at the infrahistologic level. J Am Soc Nephrol. 2017;28(2):678–690. doi:10.1681/ASN.2016020218
   PubMed Web of Science ®Google Scholar
• Schardt JA, Weber D, Eyholzer M, et al. Activation of the unfolded protein response is associated with favorable prognosis in acute myeloid leukemia. Clin Cancer Res. 2009;15(11):3834–3841. doi:10.1158/1078-0432.CCR-08-2870
   PubMed Web of Science ®Google Scholar